Evaluation of CYP2D6 phenotype in the Yoruba Nigerian population
- 17 July 2017
- journal article
- research article
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 10 (10) , 1145-1152
Abstract
Background: There is a lack of information on CYP2D6, a major metabolizing enzyme, in Africa ethnic nationalities. The objective was to determine CYP2D6 phenotype in Yoruba Nigerians using dextromethorphan (DEX). Method: A total of 89 healthy volunteers received 30 mg of DEX orally followed by blood and urine sample collection at 3-hour and over 8 h post-dose, respectively. DEX and dextrorphan (DOR) concentrations were determined using High Performance Liquid Chromatography (HPLC). The metabolic ratio (MR, DEX/DOR) were plotted for the phenotype determination. Results: The log MR that separated poor (PMs) from normal metabolizers (NMs) was 0.28 and 0.75 for urine and plasma, respectively. Two subjects (2.3%) identified as PMs had a mean MR of 17 and 3.2 in plasma and urine, significantly higher than that of NMs (p < .0001). A positive correlation between urine and plasma MR was noted. Conclusion: The prevalence of PMs in the Yoruba Nigerians was similar to that reported among blacks.Keywords
Funding Information
- National Institute of Mental Health (K08MH098794)
This publication has 54 references indexed in Scilit:
- Serum dextromethorphan/dextrorphan metabolic ratio for CYP2D6 phenotyping in clinical practiceJournal of Clinical Pharmacy and Therapeutics, 2012
- Polymorphism of Human Cytochrome P450 2D6 and Its Clinical SignificanceClinical Pharmacokinetics, 2009
- Non-response to consecutive antidepressant therapy caused by CYP2D6 ultrarapid metabolizer phenotypeInternational Journal of Neuropsychopharmacology, 2008
- Incidence of fatal adverse drug reactions: a population based studyBritish Journal of Clinical Pharmacology, 2007
- Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic PolymorphismsThe Journal of Clinical Pharmacology, 2004
- A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatmentBritish Journal of Clinical Pharmacology, 2003
- Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African populationPharmacogenetics and Genomics, 1999
- CYP2D6 polymorphism in a Gabonese population: contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotypeBritish Journal of Clinical Pharmacology, 1999
- CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medicationPharmacogenetics, 1997
- Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in NigeriansPharmacogenetics, 1992